Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001380522 | SCV001578605 | pathogenic | Mucopolysaccharidosis, MPS-III-B; Charcot-Marie-Tooth disease axonal type 2V | 2020-08-20 | criteria provided, single submitter | clinical testing | This variant disrupts the C-terminus of the NAGLU protein. Other variant(s) that disrupt this region (p.Gln706*) have been determined to be pathogenic (PMID: 9443875). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with NAGLU-related conditions. This variant is present in population databases (rs749338526, ExAC 0.002%). This sequence change results in a premature translational stop signal in the NAGLU gene (p.Val485Glyfs*31). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 259 amino acids of the NAGLU protein. |